Vytelle Ranked As One of The Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500™ read more 11/14/23
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease read more 09/13/23
Vytelle Expands to Brisbane, Australia with Sixteenth Global Bovine In Vitro Fertilisation Laboratory read more 07/13/23
